{"id":"corticosteroid-boluses-methylprednisolone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes (agitation, anxiety)"},{"rate":null,"effect":"Infection risk (immunosuppression)"},{"rate":null,"effect":"Osteoporosis (with chronic use)"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylprednisolone acts as a glucocorticoid receptor agonist, translocating to the nucleus to modulate gene expression of inflammatory mediators. When administered as boluses (high-dose pulses), it rapidly dampens immune cell activation, reduces vascular permeability, and decreases production of cytokines and chemokines. This makes it effective for acute inflammatory and autoimmune conditions requiring rapid immunosuppression.","oneSentence":"Methylprednisolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:49.734Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute exacerbations of multiple sclerosis"},{"name":"Severe autoimmune and inflammatory conditions requiring rapid immunosuppression"},{"name":"Acute transplant rejection"}]},"trialDetails":[{"nctId":"NCT02444429","phase":"PHASE3","title":"3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-09-02","conditions":"Renal Transplantation","enrollment":346},{"nctId":"NCT04394182","phase":"NA","title":"Ultra Low Doses of Therapy With Radiation Applicated to COVID-19","status":"SUSPENDED","sponsor":"Fundacion GenesisCare","startDate":"2020-04-21","conditions":"Pneumonia, Viral, Cytokine Storm","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Corticosteroid boluses Methylprednisolone","genericName":"Corticosteroid boluses Methylprednisolone","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylprednisolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Acute exacerbations of multiple sclerosis, Severe autoimmune and inflammatory conditions requiring rapid immunosuppression, Acute transplant rejection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}